摘要
目的:探讨18F标记的2-脱氧葡萄糖正电子发射断层显像技术(18PDG PET/CT)在接受R-CHOP方案(利妥昔单抗+环磷酰胺、阿霉素、长春新碱和强的松)治疗的弥漫大B细胞淋巴瘤(DLBCL)患者疗效评价中的价值。方法:回顾了我院2005.5-2007.5月收治的9例接受了R-CHOP方案治疗且接受了PET/CT评价的DLBCL患者的临床资料,分析PET/CT对这9例患者在治疗过程中的疗效评价情况,以及对治疗的指导价值。结论:PET/CT比常规方法更有能准确、有效地对DLBCL患者的治疗效果进行评价,对DLBCL进一步治疗的决策及患者的预后判断有重要的价值。
Objective： To investigate the clinical value of 18F fluorodeoxyglucose （FDG） PET in evaluating the therapeutic response of patients with diffuse large B cell lymphoma（DLBCL） treated with R-CHOP regimen （Rituximab combined with cyclophosphamide, adriamyein,vincr-stine and prednisone）. Methods We had reviewed the clinicai documents of 9 patients diagnosed as DLBCL and treated in our hospital between 2005.5 and 2007.5, receiving R-CHOP regimen and PET/CT evaluation., and made a analysis of PET/CT in evaluating the therapeutic response of these 9 patients in the process of treatment, and its value of guiding further treatment. Conclusion： PET/CT is able to evaluate patients＇ response to treatment more accurately and effectively than traditional methods, and of great significance in making further treatment strategies and predicting prognosis for patients with DLBCL.
出处
《中国医疗器械信息》
2008年第6期80-81,83,共3页
China Medical Device Information
